Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

y also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/46q6x8/2015_strategies ... "2015 Strategies in the Home/Self Testing Market" ... 175-page report provides analysis of the major home/self ... pregnancy, ovulation, and occult blood. The report presents ... competitive profiles. The growing economic pressures ...
(Date:7/1/2015)...  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... commercialization of proprietary compounded drug formulations, today announced ... market closing bell on Thursday, July 2, 2015.  ... Go Dropless™ campaign since its launch in April ... annually in the U.S. and more than 4.3 ...
(Date:7/1/2015)... 1, 2015 Lupin , ... Total Number of MPP Sub-licensees to Fourteen Companies ... (MPP) announced the rapid expansion of its network of generic ... projects to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and ... promising new HIV medicine the MPP licensed from ViiV Healthcare ...
Breaking Medicine Technology:2015 Strategies in the Home/Self Testing Market 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3
... Oct. 12 mPay Gateway, the leader in ... the leader in software, services, information, and connectivity ... point-of-care patient payment technology to Allscripts practice management ... U.S. health care payment system is shifting to ...
... TEL AVIV, Israel, October 12 Elbit Imaging Ltd.,(NASDAQ: ... 9 ,2009 it sold a,total of 4,794,292 ordinary shares ... ("Plaza"), to a number of Polish,institutional investors. The aggregate ... million (approximately $10.6 million),representing a price of 6.5 Polish ...
Cached Medicine Technology:mPay Gateway Teams With Allscripts to Provide Point-of-Care Patient Payment Tools to Physician Practices Nationwide 2Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares 2Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares 3
(Date:7/1/2015)... ... 2015 , ... The Collaborative for Children and Families (CCF) announced that it ... allow CCF to improve quality of care and save costs for the child welfare ... many changes in New York’s Medicaid system. Experts agree that children need thorough solutions ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Summer recess has ... teenagers to fix noses and chins with plastic surgery when they’re looking for a ... more than 236,000 cosmetic procedures were performed on patients ages 19 and younger in ...
(Date:7/1/2015)... ... 2015 , ... The 28th annual Charity Horse Show hosted by the Mid-South ... 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will again benefit ... Elvis impersonator, a silent auction and concessions. , Horses and riders from around the ...
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner with ... Cities on Saturday, August 1, at Spring Lake Park High School. , During the ... $1 million worth of goods and services including free food, health services, family portraits, ...
(Date:7/1/2015)... ... 2015 , ... RowdMap Inc. is a proud participant on ... Identifying the High-Cost Patient Population: Insights from the Health Care Transformation Task Force.” ... . , The Healthcare Transformation Task Force is a group of private sector ...
Breaking Medicine News(10 mins):Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3
... study is the first to examine the effectiveness of ... among African-Americans. The study found that African-American women were ... to treating substance abuse, but their substance-abuse issues continued. ... in the University of Cincinnati Department of Psychology, is ...
... time that omega-3 in fish oil could "substantially and significantly" ... the University of Bristol study, funded by Arthritis Research UK ... omega-3-rich diets fed to guinea pigs, which naturally develop osteoarthritis, ... diet. The research is a major step forward in ...
... in science and the development of new technology obtained ... the last few years will be the topics of ... Week, which will be held from October 24-26 in ... Research Foundation (FAPESP), the National Science Foundation, Ohio State ...
... , MONDAY, Oct. 17 (HealthDay News) -- ,Fast ... the same vehicle are among the reasons why thousands of ... according to new research. The findings were to be ... Conference and Exhibition in Boston. According to the AAP, ...
... global atlas charts prospects for malaria elimination by offering ... declining in many parts of the globe. The "Atlas ... the disease and provides a visual tool to help ... Created by the Global Health Group at the University ...
... at the University of Pennsylvania School of Nursing have found ... reporting premature infants are five times more likely to have ... some born as small as about a pound, were followed ... journal Pediatrics , one of the most remarkable of ...
Cached Medicine News:Health News:Research examines approaches to treating substance abuse among African-Americans 2Health News:Omega-3 fatty acids shown to prevent or slow progression of osteoarthritis 2Health News:FAPESP Week symposium discusses scientific cooperation between Brazil and the US 2Health News:FAPESP Week symposium discusses scientific cooperation between Brazil and the US 3Health News:FAPESP Week symposium discusses scientific cooperation between Brazil and the US 4Health News:FAPESP Week symposium discusses scientific cooperation between Brazil and the US 5Health News:Too Many Kids Injured in ATV Crashes, Study Finds 2Health News:Malaria elimination maps highlight progress and prospects 2Health News:Malaria elimination maps highlight progress and prospects 3Health News:Malaria elimination maps highlight progress and prospects 4Health News:Low birthweight infants five times more likely to have autism 2
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
Medicine Products: